The Plasma Fractionation Market focuses on the collection, separation, purification, and processing of human plasma to produce valuable plasma-derived medicinal products. These products include immunoglobulins, albumin, coagulation factors, protease inhibitors, and other specialized plasma proteins used in the treatment and management of a wide range of medical conditions.
Plasma-derived therapies play an important role in immunology, hematology, neurology, critical care, and other areas of healthcare. Immunoglobulins are used for immune deficiencies and several autoimmune and neurological conditions, while albumin and coagulation factors support patients requiring critical care and treatment for bleeding disorders.
According to Market Research Future, the global Plasma Fractionation Market was valued at approximately USD 41.4 billion in 2025 and is projected to reach USD 98.8 billion by 2035, expanding at a CAGR of around 9.1% during the forecast period.
Increasing demand for plasma-derived medicines, the rising prevalence of immune and rare disorders, expansion of plasma collection networks, and improvements in fractionation technologies are supporting market development. Growing efforts by governments and healthcare organizations to strengthen domestic plasma supplies are also creating new opportunities for the industry.
Get Free Sample PDF Brochure:
Plasma Fractionation Market Sample Request: https://www.marketresearchfuture.com/sample_request/7397
Market Drivers
Increasing Prevalence of Immune and Rare Disorders
The growing incidence and diagnosis of immune deficiencies, autoimmune disorders, hemophilia, and other rare diseases is increasing the need for plasma-derived therapies. Immunoglobulins and coagulation factors are particularly important in long-term disease management, supporting consistent demand for fractionated plasma products.
Rising Demand for Immunoglobulin Therapies
Immunoglobulin products have become an important part of treatment for several immune and neurological conditions. Both intravenous and subcutaneous immunoglobulin therapies are increasingly used in clinical practice, making immunoglobulins a major contributor to plasma fractionation demand.
Expansion of Plasma Collection Infrastructure
The availability of sufficient plasma is essential for producing plasma-derived medicines. Investments in plasma donation centers, collection networks, processing facilities, and supply-chain infrastructure are helping manufacturers increase production capacity and improve the reliability of plasma supplies.
Technological Advancements
Modern fractionation facilities are adopting improved centrifugation, chromatography, precipitation, filtration, purification, and viral-inactivation technologies. These developments can improve manufacturing efficiency, product consistency, safety, and recovery of valuable plasma proteins.
Growing Healthcare Expenditure
Increasing healthcare spending and improved access to specialized treatments are supporting the use of plasma-derived therapies. As healthcare systems expand their ability to diagnose and manage rare, immune, neurological, and bleeding disorders, demand for plasma products can increase.
Focus on Domestic Plasma Supply
Governments and healthcare organizations are increasingly interested in strengthening domestic supplies of plasma-derived medicines. Reducing dependence on imported products and improving national supply resilience can encourage investment in plasma collection and fractionation capacity.
Market Challenges
Complex Plasma Collection Process
Plasma fractionation depends on a consistent supply of qualified human plasma. Collection requires donor recruitment, eligibility screening, testing, storage, transportation, and careful handling, making the supply chain complex and resource-intensive.
High Manufacturing Costs
Plasma-derived products require sophisticated processing facilities, specialized equipment, extensive quality testing, and stringent safety controls. These requirements can increase manufacturing expenses and create barriers for new market participants.
Regulatory Requirements
Plasma-derived medicines are subject to strict regulatory and quality requirements because they originate from human biological material. Manufacturers must comply with regulations related to donor screening, pathogen testing, manufacturing, purification, storage, and product quality.
Supply Chain Constraints
Plasma collection and fractionation involve multiple stages and require controlled storage and transportation. Disruptions in donor availability, logistics, manufacturing capacity, or international trade can affect the availability of plasma-derived products.
Limited Plasma Donation in Some Regions
Insufficient awareness about plasma donation and differences in donation infrastructure can create regional shortages. Increasing public awareness and expanding collection centers are therefore important for improving long-term plasma availability.
Browse In-depth Market Research Report on Plasma Fractionation Market:
Plasma Fractionation Market Research Report: https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397
Market Segmentation
By Product Type:
Immunoglobulin: Immunoglobulins are among the most important products obtained through plasma fractionation. They are used in the management of primary and secondary immune deficiencies, autoimmune diseases, and several neurological disorders. The broad clinical applications of immunoglobulins make this an important market segment.
Albumin: Albumin is widely used in hospitals and critical-care settings for conditions requiring plasma volume replacement and management of specific medical situations. Its established clinical applications support continued demand.
Coagulation Factors: Plasma fractionation produces several coagulation factor products used to manage bleeding disorders. Factor VIII, Factor IX, fibrinogen, von Willebrand factor, and other concentrates can support patients with inherited or acquired coagulation deficiencies.
Protease Inhibitors: Protease inhibitors represent a specialized category of plasma-derived products used for selected therapeutic applications. Although smaller than major product categories, they remain an important part of the overall plasma-derived product portfolio.
By Application:
Neurology: Plasma-derived immunoglobulins are used in the management of certain neurological disorders. Growing diagnosis and treatment of immune-mediated neurological conditions can support demand within this application segment.
Hematology: Hematology represents an important application area because coagulation factors and other plasma-derived products are used in the management of bleeding and blood-related disorders.
General Medicine: Plasma-derived products are used across various medical situations, including immune disorders, replacement therapies, and other conditions requiring specialized plasma proteins.
Immunology: Immunology is a major application area for plasma fractionation because immunoglobulin therapies play an important role in treating immune deficiencies and selected autoimmune disorders. MRFR identifies immunology as a leading application segment.
By End-User:
Hospitals: Hospitals are major users of plasma-derived medicines because they manage patients requiring immunoglobulins, albumin, coagulation factors, and other specialized therapies.
Ambulatory Surgical Centers: Ambulatory surgical centers can use plasma-derived products in selected procedures and treatment settings, particularly where specialized blood-related therapies are required.
Blood Banks: Blood banks play an important role in plasma collection, processing, storage, and distribution. Their involvement helps support the broader supply chain required for plasma fractionation.
Pharmaceutical Companies: Pharmaceutical and biopharmaceutical companies manufacture, process, distribute, and develop plasma-derived medicinal products. Their investments in production capacity and technology are important for market expansion.
By Technology:
Centrifugation: Centrifugation is used to separate plasma and other blood components based on differences in density. It remains an important technology in plasma processing.
Chromatography: Chromatographic techniques support the purification and separation of specific plasma proteins. Advances in chromatography can improve product purity and manufacturing efficiency.
Precipitation: Precipitation methods separate plasma proteins according to their physical and chemical properties. These methods have long been used in plasma fractionation and continue to form part of modern processing systems.
Filtration: Filtration technologies are used during different stages of plasma processing and purification. Modern filtration systems can contribute to improved process control and product quality.
Regional Insights
North America
North America represents a leading region in the global Plasma Fractionation Market. The region benefits from advanced healthcare infrastructure, established plasma collection networks, high demand for plasma-derived therapies, and the presence of major manufacturers. MRFR reports that North America accounted for more than 45% of global market revenue in 2024.
Europe
Europe is another important market supported by established healthcare systems, regulatory frameworks, specialized treatment facilities, and demand for immunoglobulins, albumin, and coagulation products. MRFR estimates that the European market was valued at approximately USD 9.55 billion in 2024.
Asia-Pacific
Asia-Pacific is expected to provide significant growth opportunities as healthcare infrastructure improves and access to advanced therapies expands. Countries such as China, Japan, India, South Korea, and Australia are increasing their healthcare capabilities and developing greater awareness of plasma-derived treatments.
Growing investment in plasma collection, pharmaceutical manufacturing, and healthcare services can strengthen the regional plasma fractionation ecosystem. Increasing demand for treatment of immune deficiencies, neurological disorders, bleeding disorders, and critical-care conditions is also supporting market development.
Latin America, Middle East & Africa
Latin America, the Middle East, and Africa represent developing opportunities for plasma fractionation. Improvements in healthcare infrastructure, increasing awareness of plasma donation, and efforts to expand access to specialized therapies can support market growth.
Investment in local plasma collection and processing infrastructure may become particularly important in countries seeking to improve the security of plasma-derived medicine supplies.
Key Players
Major companies participating in the global Plasma Fractionation Market include:
Grifols
CSL Behring
Takeda Pharmaceutical Company Limited
Octapharma
Kedrion S.p.A.
Biotest AG
LFB Group
Hualan Biological Engineering Inc.
These companies are involved in plasma collection, fractionation, manufacturing, research, and commercialization of plasma-derived therapies.
Future Outlook
The Plasma Fractionation Market is expected to maintain strong growth as healthcare systems face increasing demand for plasma-derived therapies. Rising rates of immune deficiencies, autoimmune disorders, bleeding disorders, neurological diseases, and other conditions requiring plasma-based treatments are expected to remain important growth factors.
Immunoglobulins are likely to continue playing a central role because of their wide clinical use and recurring treatment requirements. Albumin and coagulation factors will also remain important products because of their applications in hospitals, hematology, critical care, and specialized medicine.
Technological progress in plasma collection, purification, chromatography, filtration, pathogen reduction, and automated manufacturing can improve production efficiency and product safety. At the same time, expansion of plasma donation networks may help manufacturers address supply constraints.
Another important opportunity is the development of domestic plasma infrastructure. Countries seeking greater self-sufficiency in plasma-derived medicines are expected to invest in collection centers, fractionation facilities, and supply-chain capabilities.
MRFR projects the global market to increase from approximately USD 45.1 billion in 2026 to USD 98.8 billion by 2035 at a CAGR of about 9.1%, highlighting the industry’s substantial long-term growth potential.
Overall, increasing clinical demand, technological innovation, expanding plasma collection capacity, and greater emphasis on supply security are expected to shape the future of the global plasma fractionation industry.
Related Reports:
Strengthen your strategy with data-backed research insights:
Medical Robotics Market Trends
Medical Robotics Market Growth
About Market Research Future:
Market Research Future (MRFR) is a global market research company that provides market intelligence and research reports across healthcare, technology, chemicals, energy, and other industries. Its research covers market trends, growth factors, competitive landscapes, technologies, applications, regional developments, and industry opportunities.
MRFR’s research is intended to help organizations evaluate market conditions, identify emerging opportunities, understand competitive environments, and support strategic business decisions.
Contact:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com
